This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Rheumatic aortic valve diseases류마티스 대동맥판질환

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: I06 (Rheumatic aortic valve diseases) | Special Copayment Reduction: V192 (Special copayment reduction for heart disease: 5% copayment for up to 30 days from the registration date)
B. SynonymsRheumatic aortic stenosis (I06.0), rheumatic aortic regurgitation/insufficiency (I06.1), rheumatic aortic stenosis with regurgitation (I06.2)
C. Adult onsetRheumatic aortic stenosis progresses over 20–40 years after rheumatic fever and becomes symptomatic mainly in the 40s–60s. Regurgitation may appear earlier and can remain asymptomatic for a considerable period.
1. HistoryLaennec's auscultation technique in the 18th century. Surgical treatment established with the introduction of prosthetic valves in the 1960s. The first successful TAVI (transcatheter aortic valve implantation) in 2002 (Cribier) opened the era of nonsurgical treatment.
2. CausesRepeated rheumatic endocarditis causes thickening, adhesion, and calcification of the valve cusps. Aortic regurgitation results from retraction and shortening of the cusps, or stenosis and regurgitation coexist. Almost always accompanied by mitral involvement.
3. GeneticsImmunogenetic determinants of susceptibility to rheumatic fever (HLA-DR-related) act indirectly. Polymorphisms in TGF-β pathway genes affecting the rate of aortic valve fibrosis are under study.
4. General epidemiologyIsolated aortic valve involvement in rheumatic heart disease is about 5–10% of the total. Combined with the mitral valve in 20–35%. In developed countries, degenerative calcific aortic stenosis is far more common than rheumatic.
5. PathophysiologyRheumatic endocarditis → commissural fusion and thickening of the aortic cusps → reduced valve opening (stenosis). Or incomplete valve closure due to cusp retraction (regurgitation). Regurgitation sometimes appears first without commissural fusion.
6. SymptomsStenosis: angina, syncope, dyspnea (heart failure). Regurgitation: palpitations, exercise intolerance, dyspnea. Acute severe regurgitation: rapid pulmonary edema, cardiogenic shock.
7. SignsStenosis: systolic ejection murmur, single second heart sound, slow-rising pulse. Regurgitation: high-pitched diastolic murmur, wide pulse pressure, Corrigan pulse, Austin Flint murmur.
8. ScreeningRegular echocardiography in patients with a history of rheumatic fever. Add echocardiography when a murmur is heard on auscultation. In asymptomatic severe regurgitation, following left ventricular size and function is key.
9. DiagnosisEchocardiography: valve area (continuity equation), mean pressure gradient, regurgitation severity (PISA method, vena contracta). Cardiac CT to evaluate anatomy and calcification. Cardiac catheterization for pressure measurement.
10. TreatmentSevere symptomatic stenosis: surgical aortic valve replacement (SAVR) or TAVI. Severe regurgitation + symptoms or left ventricular dysfunction: SAVR. TAVI has limited effectiveness in rheumatic disease (insufficient calcification of the landing zone).
11. PrognosisUntreated symptomatic severe aortic stenosis: 2-year survival about 50%. 10-year survival after valve replacement about 70%. Regurgitation: progression from asymptomatic to symptomatic may take decades.
12. PreventionPrevention of rheumatic recurrence by secondary prophylaxis (benzathine penicillin G) is key to preventing progression of valve damage. Regular follow-up in asymptomatic regurgitation to identify the optimal timing of surgery.
13. References2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease … and 9 other papers

1. History

Clinical recognition of aortic valve disease began with the development of auscultation in the 18th–19th centuries. When René Laennec invented the stethoscope in 1819 and linked heart murmurs to valvular disease, the auscultatory features of aortic stenosis and regurgitation began to be systematized. In the late 19th century, William Osler and others described peripheral pulse findings associated with aortic regurgitation (Corrigan pulse, Duroziez sign, Quincke sign, etc.).

That rheumatic heart disease is one of the main causes of aortic valve disease was established through pathological studies in the late 19th century. However, until the mid-20th century, there were no particular options other than medical treatment. Only in the 1960s, when Harken, Starr, Carpentier, and others developed mechanical and bioprosthetic tissue valves and applied aortic valve replacement by open-heart surgery (SAVR, surgical aortic valve replacement) clinically, did effective treatment become possible.

In 2002, Alain Cribier of France performed the world's first successful transcatheter aortic valve implantation (TAVI) in a human. This technique subsequently developed rapidly, and its indications are now expanding from high to low surgical risk groups. However, in rheumatic aortic stenosis, calcification is often insufficient and TAVI anchoring is unstable, so the use of TAVI in rheumatic etiology must still be decided cautiously. Recently, new-generation neocuspidalization surgical techniques are being studied as a new surgical alternative for rheumatic aortic valve disease.


2. Causes

The direct cause of rheumatic aortic valve disease is structural damage to the aortic valve cusps from repeated rheumatic endocarditis. With each episode of acute rheumatic endocarditis, small verrucous vegetations form on the free edges of the aortic cusps, and fibrotic scarring accumulates as they heal. As this process repeats, ① thickening and stiffening of the cusps, ② fusion of the commissures (the main mechanism of stenosis), and ③ retraction and shortening of the cusps (the main mechanism of regurgitation) occur.

In rheumatic aortic stenosis, commissural fusion combined with calcification reduces the valve orifice area. In rheumatic aortic regurgitation, diastolic valve closure becomes incomplete due to fibrotic retraction and shortening of the cusps, or diastolic regurgitation occurs due to commissural adhesion between cusps. Aortic valve disease of rheumatic origin is almost always accompanied by mitral involvement, and isolated aortic valve involvement is rare. Causes of nonrheumatic aortic stenosis include early calcification of a bicuspid aortic valve, senile degenerative calcific stenosis, and congenital stenosis.


3. Genetics

The genetic basis of rheumatic aortic valve disease is fundamentally the immunogenetic factors involved in susceptibility to rheumatic fever. Specific alleles of HLA-DR genes (HLA-DR7, HLA-DRB1, etc.) affect the risk of rheumatic fever and cardiac involvement and thereby indirectly influence the occurrence and severity of aortic valve damage. The intensity of an individual's autoimmune response and the level of chronic inflammatory response are also partly genetically determined.

Studies are under way suggesting that polymorphisms in genes involved in fibrosis and calcification of aortic valve tissue, particularly the TGF-β signaling pathway (TGF-β1, TGFBR1, TGFBR2 genes), may affect the rate of progression of valve damage. In addition, NOTCH1 gene variants are known to be related to the calcification tendency of nonrheumatic bicuspid aortic valves, but their role in rheumatic etiology is still unclear. Currently, genetic testing is not routinely used clinically in rheumatic aortic valve disease.


4. General epidemiology

In rheumatic heart disease, isolated aortic valve involvement accounts for only about 5–10% of the total, and combined involvement with the mitral valve occurs in 20–35% of all patients with rheumatic heart disease. Among all causes of aortic stenosis in developed countries, degenerative calcific stenosis (senile, bicuspid origin) is the most common, and rheumatic stenosis is declining. In contrast, in low- and middle-income countries, rheumatic disease is still one of the main causes of aortic stenosis.

Rheumatic aortic regurgitation can present at a relatively younger age (20s–40s) than stenosis and is slightly more common in men. Because rheumatic aortic valve disease is often accompanied by mitral valve disease, it is often dealt with within the category of rheumatic multiple valve disease (I08). Worldwide, a considerable proportion of people with rheumatic heart disease have aortic valve involvement, which contributes to the need for valve replacement and an increased cardiac surgical burden.


5. Pathophysiology

Fibrosis progresses as thrombi are repeatedly deposited on and heal at the aortic cusp commissures due to rheumatic endocarditis. Commissural fusion strengthens the bonds between the three cusps (right coronary, left coronary, and noncoronary cusps), gradually reducing the valve orifice area. As fibrosis progresses, the cusps retract and stiffen and cannot close completely in diastole, resulting in aortic regurgitation. Therefore, rheumatic aortic stenosis is often accompanied by regurgitation (I06.2).

Hemodynamically, in severe aortic stenosis, left ventricular outflow resistance increases and left ventricular pressure rises, and concentric hypertrophy of the left ventricle develops to compensate. The hypertrophied left ventricle has increased oxygen demand and reduced coronary flow reserve, causing angina, and when compensatory mechanisms fail it progresses to left ventricular dilation and heart failure. In severe aortic regurgitation, the left ventricle is volume overloaded by the diastolic regurgitant volume, leading to eccentric hypertrophy and left ventricular dilation, and ultimately left ventricular dysfunction.


6. Symptoms

The classic triad of symptoms of rheumatic aortic stenosis is angina pectoris, syncope, and dyspnea due to heart failure. Angina is caused by increased oxygen demand of the hypertrophied left ventricle and reduced coronary flow reserve and can occur even without coronary artery disease. Syncope occurs mainly when cerebral blood flow decreases due to the combined effects of failure to increase cardiac output during exercise and decreased peripheral vascular resistance. The risk of death rises sharply within an average of 5 years after the onset of angina, 3 years after syncope, and 1–2 years after heart failure.

The symptoms of severe aortic regurgitation are mainly dyspnea due to pulmonary venous hypertension and palpitations due to increased cardiac output and forceful beating of the dilated left ventricle, especially pounding when lying down at night. Reduced exercise tolerance and fatigue are also common. In acute severe aortic regurgitation (due to infective endocarditis, aortic dissection, etc.), there is no time for circulatory adaptation, so it becomes an emergency in which severe pulmonary edema and cardiogenic shock suddenly develop.


7. Signs

The main auscultatory finding of aortic stenosis is a systolic ejection murmur heard at the right second intercostal space (aortic auscultation area), which radiates toward the neck and is harsh and rough. When cardiac function declines with severe stenosis, the intensity of the murmur may actually decrease. The aortic component of the second heart sound (A2) is diminished or absent, and in severe cases a single S2 (only P2 heard) appears. The pulse is characterized by pulsus parvus et tardus, with a slow upstroke and small amplitude. The difference between systolic and diastolic pressure (pulse pressure) narrows.

The sign of aortic regurgitation is characteristically a wide pulse pressure, with high systolic and low diastolic pressure. The Corrigan pulse (water-hammer pulse) is a pulse form with a rapid rise and rapid fall, palpated at the wrist. A high-pitched diastolic aortic regurgitation murmur is heard along the left sternal border. The Austin Flint murmur is a diastolic murmur produced when the regurgitant jet shakes the anterior mitral leaflet in severe regurgitation, suggesting functional mitral stenosis. Various peripheral vascular signs also appear, such as Quincke's sign (pulsation of nail bed capillaries) and Duroziez's sign (a double murmur auscultated over the femoral artery).


8. Screening

Screening for rheumatic aortic valve disease is done by regular echocardiographic follow-up in all patients with a history of rheumatic fever or rheumatic heart disease. Because aortic valve involvement in rheumatic heart disease is often accompanied by mitral involvement, the aortic valve is also evaluated in patients with confirmed mitral valve disease.

In patients with asymptomatic severe aortic regurgitation, following changes in left ventricular size and function is key to deciding when to treat. Because surgery should be planned before the left ventricular end-systolic diameter (LVESD) exceeds 50mm or the left ventricular ejection fraction (LVEF) falls below 50%, echocardiography is performed every 6 months to 1 year in asymptomatic severe regurgitation. In asymptomatic severe aortic stenosis as well, the onset of symptoms, valve area, left ventricular function, and exercise tolerance are evaluated regularly. Exercise stress testing is useful for confirming whether patients with severe stenosis who report being asymptomatic are truly asymptomatic.


9. Diagnosis

Echocardiography is central to diagnosis and severity assessment. In aortic stenosis, peak velocity (Vmax), mean pressure gradient, and valve area (continuity equation, AVA) are measured by Doppler echocardiography. Severe aortic stenosis is defined as Vmax ≥4m/s, mean gradient ≥40mmHg, and AVA ≤1.0cm² (or AVAi ≤0.6cm²/m² body surface area). In rheumatic disease, commissural fusion is characteristic, and uniform thickening of the three cusps and retraction of the cusp tips (rollup) are observed.

The severity of aortic regurgitation is assessed by the width of the regurgitant jet (vena contracta, PISA method), the regurgitant fraction, systolic-diastolic flow reversal in the aorta, and the degree of left ventricular dilation. Cardiac CT is essential for the degree of valve calcification (Agatston score), aortic dimensions, and TAVI procedure planning. Cardiac catheterization is performed when echocardiographic and clinical findings are discordant or when concomitant coronary artery disease is suspected.


10. Treatment

The standard treatment for severe symptomatic aortic stenosis is surgical aortic valve replacement (SAVR) or, in elderly and high-risk patients, TAVI. In rheumatic aortic stenosis, TAVI should be applied cautiously because of the risk of unstable valve fixation due to commissural fusion and insufficient calcification. Recently, experience in treating rheumatic aortic stenosis with new-generation self-expanding TAVI devices has been increasing, but long-term outcome data are still limited.

In severe aortic regurgitation, surgical treatment (SAVR or valve repair) is recommended ① when symptoms are present, or ② when asymptomatic but with LVEF <50% or LVESD >50mm. Valve repair (neocuspidalization, etc.) has the advantage of avoiding anticoagulation in young patients and is also being tried in rheumatic etiology. Medical treatment includes blood pressure control when hypertension is present (ACE inhibitors, calcium channel blockers) and heart failure treatment, and caution is needed with vasodilator use in aortic stenosis. Secondary prophylaxis (regular benzathine penicillin G administration) should be continued even after valve replacement.


11. Prognosis

The natural history of symptomatic severe aortic stenosis is very poor. Median survival of an average of 5 years after onset of angina, 3 years after syncope, and 1–2 years after onset of heart failure has been reported, and 2-year survival is below approximately 50%. Therefore, early surgical or interventional treatment once symptoms appear is decisive for improving survival. Ten-year survival after valve replacement is approximately 70%, and appropriate anticoagulation management is important when a mechanical valve is used.

The natural history of asymptomatic severe aortic regurgitation is relatively favorable, with approximately 4–6% per year developing symptoms or left ventricular dysfunction. However, once left ventricular dysfunction develops, recovery of left ventricular function may be incomplete even after surgery, so it is important to decide the timing of surgery before dysfunction occurs. The prognosis of rheumatic aortic valve disease depends largely on the presence and severity of mitral valve involvement and on adherence to secondary prophylaxis.


12. Prevention

Prevention of rheumatic aortic valve disease applies the same primary and secondary prevention strategies as for rheumatic fever. Secondary prophylaxis (benzathine penicillin G intramuscularly every 3–4 weeks; oral sulfadiazine or erythromycin in case of penicillin allergy) is the most important means of preventing cumulative progression of valve damage. For the duration of secondary prophylaxis, lifelong administration is considered when residual valve lesions are present. In patients with asymptomatic aortic regurgitation, aggressive treatment of hypertension helps suppress progression of left ventricular dilatation. Secondary prophylaxis should also be continued in postoperative patients to prevent new valve damage from rheumatic recurrence or early degeneration of bioprosthetic valves.


13. References

  1. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease. Journal of the American College of Cardiology. 2021;77(4):e25-e197. DOI: 10.1016/j.jacc.2020.11.018. PMID: 33342586.

  2. Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. European Heart Journal. 2022;43(7):561-632. DOI: 10.1093/eurheartj/ehab395. PMID: 34453165.

  3. Cribier A, Eltchaninoff H, Bash A, et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis. Circulation. 2002;106(24):3006-3008. DOI: 10.1161/01.CIR.0000047200.36165.B8. PMID: 12473543.

  4. Carabello BA, Paulus WJ. Aortic stenosis. Lancet. 2009;373(9680):956-966. DOI: 10.1016/S0140-6736(09)60211-7. PMID: 19232707.

  5. Maurer G. Aortic regurgitation. Heart. 2006;92(7):994-1000. DOI: 10.1136/hrt.2004.042614. PMID: 16775109.

  6. Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368(9540):1005-1011. DOI: 10.1016/S0140-6736(06)69208-8. PMID: 16980116.

  7. Webb JG, Mack MJ, White JM, et al. Transcatheter aortic valve implantation within degenerated aortic surgical bioprostheses. JACC: Cardiovascular Interventions. 2017;10(7):686-696. DOI: 10.1016/j.jcin.2016.11.049. PMID: 28385407.

  8. Généreux P, Piazza N, Alu MC, et al. Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research. Journal of the American College of Cardiology. 2021;77(21):2717-2746. DOI: 10.1016/j.jacc.2021.02.009. PMID: 33888385.

  9. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. New England Journal of Medicine. 2010;363(17):1597-1607. DOI: 10.1056/NEJMoa1008232. PMID: 20961243.

  10. Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. Journal of the American College of Cardiology. 2008;52(13):e1-e142. DOI: 10.1016/j.jacc.2008.05.007. PMID: 18848134.